David Haddox

David Haddox was a pain specialist who became Purdue Pharma’s point man for OxyContin, carrying the company’s assurances about addiction risk into medical training and public disputes. In the communities where doctors and officials were documenting misuse, his insistence that pain remained undertreated collided with reports of overdoses, injection, and drug-related crime. His role connects the reassuring language used to promote the drug with the growing resistance of people who were witnessing its consequences.

Identity and Role at Purdue Pharma

Haddox represented Purdue Pharma’s medical case for OxyContin’s safety. In a 1996 company training session for doctors, he advanced the claim that addiction caused by medical treatment was “exquisitely rare.” He also told audiences that, when opioids were taken as prescribed, the risk of addiction was one-half of 1 percent. The statistic did more than describe a risk: in the company’s presentation, it helped make the new drug seem compatible with routine medical care.

Purdue’s message was not confined to a narrow group of patients. Haddox promoted OxyContin for chronic pain beyond cancer, while the company’s sales representatives carried the argument to doctors and dentists throughout the United States. The sales pitch framed prescribing as responsible and compassionate for a wide range of conditions, including moderate back injuries, wisdom-tooth surgery, bronchitis, and temporomandibular joint disorder. In this account, Haddox is both a medical specialist and a public-facing advocate for a commercial campaign that sought to broaden opioid prescribing.

The company’s language met a medical culture already changing. When OxyContin was introduced in 1996, health care institutions were elevating pain assessment, and new standards gave pain heightened importance in treatment. Purdue presented the drug as a dependable answer to that demand. Haddox’s low-risk claims helped bridge the company’s product to an expanding expectation that pain should be treated more assertively.

Warnings from Virginia

By 2000, Art Van Zee, a physician in Lee County, was writing directly to Haddox about patterns he saw among patients: injection, repeated overdoses, abscesses, and rising hepatitis C. In his first letter, dated August 20, Van Zee asked Haddox to investigate Purdue’s prescribing in the region and warned that the scale of the problem was difficult to overstate. He compared the affected area to places that had served as early warning sites during the HIV epidemic. Purdue’s response was to send Van Zee and his medical partner adverse-event reporting forms.

Van Zee also organized a forum for doctors and families, bringing Yale University substance-use experts to explain the physical and psychological distress of opioid withdrawal. When the researchers recommended that physicians consider other drugs less prone to abuse for patients with severe pain, a Purdue representative who had been sitting in the audience rose to object. The response focused on inadequate pain treatment rather than OxyContin’s potential for abuse. The passage does not identify that representative by name, but it places Haddox’s public argument within a wider company position that resisted interpreting misuse as evidence against the drug.

The conflict sharpened as reports from nearby Tazewell County, Virginia, described OxyContin-related felonies, pharmacy robberies, and people in trouble after becoming dependent on the drug. After reporter Theresa M. Clemons covered the crime, Haddox called to complain about her reporting; the account says he seemed intimidating. At a subsequent meeting with Van Zee, the county prosecutor, and local officials, Haddox acknowledged that Purdue was concerned about the coalfields but said he believed the worries were overblown. When he and his colleagues redirected discussion toward the underprescribing of narcotics, prosecutor Dennis Lee interrupted to insist that officials had never seen comparable pill-related and human tragedies.

Confrontation with Local Clinicians and Families

Van Zee’s objections included not only prescribing, but also Purdue’s promotional practices. As the meeting ended, he pulled Haddox aside and urged the company to stop giving doctors promotional freebies. Haddox answered, “How is that any different from what every other drug company does?” Van Zee replied that people did not steal from relatives or break into neighbors’ homes over blood-pressure pills. Their exchange condensed the dispute: Haddox invoked ordinary industry practice, while Van Zee pointed to harms he believed made OxyContin different.

Van Zee’s letters grew more urgent as he heard from patients who had to travel long distances for methadone maintenance. He asked Purdue to stop aggressively marketing OxyContin for noncancer pain and to reformulate the drug to make it less vulnerable to abuse. At a Purdue-funded pain-foundation meeting, the company’s emphasis on undertreated pain remained prominent. Local clinicians’ requests for a change in marketing and formulation, by contrast, treated the drug’s abuse potential as an immediate community problem rather than a hypothetical qualification to its benefits.

In March 2001, Haddox attended a meeting arranged by Van Zee between Purdue executives and concerned families. One father, a banker from Pennington Gap, described his son’s addiction and the $80,000 in savings the young man had already spent. He argued that the company should have known Lee County had a problem, given how many pills it was sending there compared with places several times larger. Chief executive Michael Friedman expressed sympathy for the family. At the end of the meeting, however, Purdue presented a planned full-page newspaper advertisement denying that it had targeted Appalachian communities or known of the drug’s abuse potential, and disputing that reformulation could be achieved quickly or easily.

The meeting had raised Van Zee’s hope that Purdue might compromise, but the proposed advertisement made that hope untenable. Sue Ella Kobak confronted Haddox, telling him, “You have done more to hurt Appalachia than the coal industry has ever thought about doing.” Haddox said he resented the implication; Kobak answered that she did not care whether he did and explained that she took the insult personally as an Appalachian scholar whose family had deep roots in the region. She left with the others. The advertisement never ran, but the encounter showed how far the company’s defensive account had separated it from the families asking it to recognize the damage.

Significance in the Account

Haddox’s significance lies in the repeated contrast between a confident general claim and mounting local testimony. He described addiction as rare and framed the central danger as undertreatment; Van Zee and public officials described injection, overdoses, hepatitis C, crime, and families depleted by addiction. Their disagreement was not simply about whether pain mattered. It was also about whether a low addiction-risk estimate could answer evidence of harm accumulating in a particular place.

The narrative also distinguishes Haddox’s public role from the broader commercial forces behind overprescribing. The account later reveals that sales-representative bonuses rose from $1 million in 1996 to $40 million in 2001, while Purdue offered free starter prescriptions and held national pain-management and speaker-training conferences. Those details place Haddox’s assurances inside a much larger system of promotion; they do not establish that he personally designed or controlled that system. His recurring presence instead gives the dispute a recognizable interlocutor: the company’s medical advocate, confronted by clinicians and families asking that claims about safety be measured against what was happening around them.